“Ger­man drug mak­er Mer­ck KGaA (MKGAY.PK) announced Mon­day that it has entered into an agree­ment with HAP­PYneu­ron, a sub­sidiary of SBT Group of France, in which Mer­ck will receive an exclu­sive license to the company’s cog­ni­tive reme­di­a­tion train­ing pro­gram for peo­ple liv­ing with mul­ti­ple scle­ro­sis or MS. Finan­cial terms of the deal were not dis­closed.

HAPPYneuron’s cog­ni­tive reme­di­a­tion pro­gram will be avail­able for inclu­sion in Merck’s Msdi­a­log plat­form for use with Rebif (inter­fer­on beta-1a)…when deemed ben­e­fi­cial for a patient by his/her health­care provider. HAP­PYneu­ron is designed to improve cog­ni­tive skills through brain train­ing by repeat­ed cog­ni­tive game train­ing exer­cis­es…

MSdi­a­log is a mul­ti-ten­ant cloud-based soft­ware sys­tem for the man­age­ment of MS that cap­tures and presents patient out­come data to enable bet­ter deci­sion-mak­ing by patients and providers. MSdi­a­log is cur­rent­ly avail­able in 24 coun­tries.”

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.